Alerts
PDF
Other content recommended for you
- Failure to adhere to study plans is the most common research error among US investigators
- Understanding FDA Regulatory Requirements for Investigational New Drug Applications for Sponsor-Investigators
- Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold
- Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981–2014: a retrospective observational study
- Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies
- Streamlining the Clinical Research Enterprise
- Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis
- Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
- The FDA, Juno Therapeutics, and the ethical imperative of transparency
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis